Genome Medical is a technology company.
Genome Medical has raised $97.0M across 4 funding rounds.
Genome Medical has raised $97.0M in total across 4 funding rounds.
Genome Medical is a technology-enabled healthcare services company specializing in telehealth genetic services, primarily focused on rare diseases.[1][4] It builds a digital platform called Genome Care Delivery that connects patients, providers, hospitals, health systems, biopharma organizations, and genetic testing labs to a nationwide network of genetic counselors and specialists for virtual consultations, testing support, clinical trial matching, and AI-driven tools.[1][2][3][4] The company solves critical access gaps in genomics care—such as long diagnostic odysseys for rare conditions affecting over 300 million people worldwide—by accelerating diagnoses, streamlining workflows, and linking patients to therapies via telehealth available in 50 states with clinicians averaging 10+ years of experience.[1][2] Growth momentum includes a January 2025 strategic pivot to rare diseases with expanded AI and trial matching, partnerships like Kaiser Permanente and Shriners Hospitals, and research outputs like a 2025 study on telehealth for 750 ATTR-CM patients.[4][6][8]
Founded in 2016 in San Francisco, California, Genome Medical emerged from the vision of co-founders Lisa Alderson (MBA), Randy Scott (Ph.D., founder of Genomic Health and executive chairman of Invitae), and Robert C. Green (MD, MPH, Harvard professor and medical geneticist).[1][3] Led by genetic counselors passionate about innovation, the company was built to make expert genetic guidance accessible amid rising demand for genomics in everyday care, starting as the first telemedicine service specializing in genomics for health systems, providers, employers, and individuals.[1][3][7] Early traction came from launching the Genome Care Delivery platform in 2019, initially targeting oncology and reproductive health to enable virtual access to specialists, followed by expansions into broader genetic services and key partnerships that addressed rural care shortages and hospital backlogs.[3][6]
Genome Medical rides the wave of precision medicine and telehealth expansion, capitalizing on AI advancements, gene therapies, and clinical trials for rare diseases amid a market shift toward specialized, virtual care.[1][4] Timing aligns with post-pandemic telehealth normalization and surging demand—rare diseases impact 300 million globally with diagnostic delays—fueled by forces like biopharma's trial recruitment needs and health systems' specialist shortages.[1][2][6] It influences the ecosystem by bridging gaps for underserved patients (e.g., rural via Shriners), enabling population-scale genomics for partners like Kaiser, and contributing research that validates telehealth efficacy, thus standardizing virtual genetics in mainstream healthcare.[6][8]
Genome Medical's rare disease pivot positions it to scale impact through AI-enhanced trial matching and navigation tools, potentially capturing more biopharma partnerships as therapies proliferate.[4] Trends like AI in clinician workflows and global gene therapy growth will propel its platform, evolving its role from access provider to ecosystem orchestrator for personalized genomics. As virtual care matures, expect deepened integrations with health systems and expanded international reach, amplifying its founding mission of hope for rare condition patients.[1][4]
Genome Medical has raised $97.0M in total across 4 funding rounds.
Genome Medical's investors include Alumni Ventures, Canaan Partners, Cota Capital, Matt Ocko, Genoa Ventures, GV, Kaiser Permanente Ventures, Mission BioCapital, Modern Venture Partners, NewView Capital, NightDragon, Parkway VC.
Genome Medical has raised $97.0M across 4 funding rounds. Most recently, it raised $60.0M Series C in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $60.0M Series C | Alumni Ventures, Canaan Partners, Cota Capital, Matt Ocko, Genoa Ventures, GV, Kaiser Permanente Ventures, Mission BioCapital, Modern Venture Partners, NewView Capital, NightDragon, Parkway VC, RTW Investments, Spark Capital, Catherine Lu, Thomas Tull | |
| Jun 1, 2020 | $14.0M Series B | Byers Capital, Canaan Partners, Genoa Ventures, Kaiser Permanente Ventures, Mission BioCapital, Andrew Schoen, Ron Bernal, NewView Capital, Walden Catalyst Ventures | |
| Jan 1, 2018 | $11.0M Series A | Canaan Partners, Genoa Ventures, Kaiser Permanente Ventures, Mission BioCapital, NewView Capital | |
| May 1, 2017 | $12.0M Series A | Canaan Partners, Genoa Ventures, Mission BioCapital, NewView Capital |